Propriedades físicas de sementes de baru em função da secagem.

O experimento teve o objetivo de efetuar a caracterização das propriedades fisicas de sementes de Baru (Dipterys alata. Vog.), provenientes da região de Sidrolândia-MS

KALE SEEDLINGS PRODUCTION IN DIFFERENT SUBSTRATES, CELL VOLUMES AND PROTECTED ENVIRONMENTS

ABSTRACT: The kale is a brassica, this vegetable presents importance on nutritional and economic patterns. The present study aimed to evaluate the effect of different substrates, trays and protected environment in the formation of kale seedlings. The experiment was conducted in two greenhouses located at the State University of Mato Grosso do Sul -MS. The first environment consisted of an agricultural greenhouse with polyethylene film cover, while the second was an agricultural nursery with monofilament screen and mesh to offer 50% of shading. In each protected environment were used 72 and 128 cells tray and six different compositions of substrates with organic material based on cassava branches (CB) and cattle manure (CM): 1) 100% CM; 2) 20% CM + 80% CB; 3) 40% CB + 60% CM; 4) 60% CB + 40% CM; 5) 80% CB + 20% and CM; 6) 100% CB. The seedlings were evaluated according to the parameters: dry mass of seedlings, stem diameter and plant height. The agricultural nursery was the most suitable for the formation of kale seedlings, with 72 cells tray and the substrate composed of organic matter with 20% of cassava branches and 80% of cattle manure

Effect of allopurinol in addition to hypothermia treatment in neonates for hypoxic-ischemic brain injury on neurocognitive outcome (ALBINO): Study protocol of a blinded randomized placebo-controlled parallel group multicenter trial for superiority (phase III)

Background: Perinatal asphyxia and resulting hypoxic-ischemic encephalopathy is a major cause of death and long-term disability in term born neonates. Up to 20,000 infants each year are affected by HIE in Europe and even more in regions with lower level of perinatal care. The only established therapy to improve outcome in these infants is therapeutic hypothermia. Allopurinol is a xanthine oxidase inhibitor that reduces the production of oxygen radicals as superoxide, which contributes to secondary energy failure and apoptosis in neurons and glial cells after reperfusion of hypoxic brain tissue and may further improve outcome if administered in addition to therapeutic hypothermia. Methods: This study on the effects of ALlopurinol in addition to hypothermia treatment for hypoxic-ischemic Brain Injury on Neurocognitive Outcome (ALBINO), is a European double-blinded randomized placebo-controlled parallel group multicenter trial (Phase III) to evaluate the effect of postnatal allopurinol administered in addition to standard of care (including therapeutic hypothermia if indicated) on the incidence of death and severe neurodevelopmental impairment at 24 months of age in newborns with perinatal hypoxic-ischemic insult and signs of potentially evolving encephalopathy. Allopurinol or placebo will be given in addition to therapeutic hypothermia (where indicated) to infants with a gestational age 65 36 weeks and a birth weight 65 2500 g, with severe perinatal asphyxia and potentially evolving encephalopathy. The primary endpoint of this study will be death or severe neurodevelopmental impairment versus survival without severe neurodevelopmental impairment at the age of two years. Effects on brain injury by magnetic resonance imaging and cerebral ultrasound, electric brain activity, concentrations of peroxidation products and S100B, will also be studied along with effects on heart function and pharmacokinetics of allopurinol after iv-infusion. Discussion: This trial will provide data to assess the efficacy and safety of early postnatal allopurinol in term infants with evolving hypoxic-ischemic encephalopathy. If proven efficacious and safe, allopurinol could become part of a neuroprotective pharmacological treatment strategy in addition to therapeutic hypothermia in children with perinatal asphyxia. Trial registration: NCT03162653, www.ClinicalTrials.gov, May 22, 2017